Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery

doi:10.1016/0378-5173(96)85200-8

International Journal of Pharmaceutics

Volume 136, Issues 1–2, 14 June 1996, Pages 117-139

https://doi.org/10.1016/0378-5173(96)85200-8 Get rights and content

Abstract

The authors firstly review the literature dealing with drug absorption sites in the gastrointestinal tract. Descriptions are given of the methods used in determining the location of these sites, and the advantages and disavantages of each method are critically discussed. The results obtained concerning the absorption sites of the drugs used in the in vivo methods studied are given in a tabular form and several factors influencing drug absorption are briefly reported. Mechanisms of drug absorption in the human body and their influence on absorption sites are examined. Finally, there is a discussion of various dosage forms which are used for targetting drug absorption to specific sites.

References (181)

A. Adson et al.
Quantitative approaches to delineate paracellular diffusion in cultures epithelial cell monolayers
J. Pharm. Sci.
(1994)
G.L. Amidon et al.
Analysis of models for determining intestinal wall permeabilities
J. Pharm. Sci.
(1980)
P. Artursson
Epithelial transport of drugs in cell culture. I: A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells
J. Pharm. Sci.
(1990)
M. Ashford et al.
An in vivo investigation into the suitability of pH dependent polymers for colonic targeting
Int. J. Pharm.
(1993)
M. Ashford et al.
Studies on pectin formulations for colonic drug delivery
J. Controlled Release
(1994)
J. Blanchard et al.
Reevaluation of the absorption of carbenoxolone using an in situ rat intestinal technique
J. Pharm. Sci.
(1990)
V.S. Chadwick et al.
Measurements of intestinal permeability using low molecular weight polyethylenglycols (PEG 400)
Gastroenterology
(1977)
V.S. Chungi et al.
Gastrointestinal sites of furosemide absorption in rats
Int. J. Pharm.
(1979)
G.M. Clarke et al.
Gastrointestinal transit of pellets of different size and density
Int. J. Pharm.
(1993)
G.M. Clarke et al.
Comparative gastrointestinal transit of pellet systems of varying density
Int. J. Pharm.
(1995)

S.S. Davis

The design and evaluation of controlled release systems for the gastrointestinal tract

J. Controlled Release

(1985)

J.T. Doluisio et al.

Drug absorption I: an in situ rat gut technique yelding realistic absorption rates

J. Pharm. Sci.

(1969)

J.T. Doluisio et al.

Drug absorption III: effect of membrane storage on the kinetics of drug absorption

J. Pharm. Sci.

(1970)

J.B. Dressman et al.

Gastrointestinal parameters that influence oral medications

J. Pharm. Sci.

(1993)

J.H. Eldridge et al.

Biodegradable microspheres as a vaccine delivery system

Mol. Immunol.

(1991)

G. Fiese et al.

Further investigations into the absorption of dextrometorphan from the rat's stomach

J. Pharm. Sci.

(1969)

D.I. Friedman et al.

Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852

J. Pharm. Sci.

(1989)

D.I. Friedman et al.

Characterization of the intestinal transport parameters for small peptide drugs

J. Controlled Release

(1990)

C.H. Gleiter et al.

Colonoscopy in the investigation of drug absorption in healthy volunteers

Gastrointestinal Endoscopy

(1985)

R. Gröning et al.

Dosage forms with controlled gastrointestinal passage -studies on the absorption of nitrofuratoin

Int. J. Pharm.

(1989)

D. Harris et al.

GI transit of potential bioadhesive formulations in man: a scintigraphic study

J. Controlled Release

(1990)

D. Harris et al.

GI transit potential bioadhesive systems in the rat

J. Controlled Release

(1990)

A.K. Hilton et al.

In vitro and in vivo evaluation of an oral sustained-release floating dosage form of amoxycillin trihydrate

Int. J. Pharm.

(1992)

N.F.H. Ho et al.

Biophysical model approaches to mechanistic transepithelial studies of peptides

J. Controlled Release

(1990)

M. Ichikawa et al.

A new multiple-unit oral floating dosage system. II: in vivo evaluation of floating and sustained-release characteristics with p-aminobenzoic acid and isosorbide dinitrate as model drugs

J. Pharm. Sci.

(1991)

H.M. Ingani et al.

Conception and in vivo investigation of peroral sustained release floating dosage forms with enhanced gastrointestinal transit

Int. J. Pharm.

(1987)

J.S. Kim et al.

Absorption of ACE inhibitors from small intestine and colon

J. Pharm. Sci.

(1994)

I. Komiya et al.

Quantitative mechanistic studies in simultaneous fluid flow and intestinal absorption using steroids as model solutes

Int. J. Pharm.

(1980)

B. Krevsky et al.

Colonic transit scintigraphy

Gastroenterology

(1986)

K.H. Antonin

Other methods in studying colonic drug absorption

P. Artursson et al.

Selective paracellular permeability in two models of intestinal absorption: cultured monolayers of human intestinal epithelial cells and rat intestinal segments

Pharm. Res.

(1993)

M. Ashford et al.

Targeting drugs to the colon: delivery systems for oral administration

J. Drug Targeting

(1994)

R. Balasubramanian et al.

Pharmacokinetics of acrivastine after oral and colonic administration

J. Clin. Pharmacol.

(1989)

Banker, G.S., Br. Patent 1,428,426...

H. Bechgaard et al.

Gut reaction to tablets and capsules. 2. Physiological factors and controlled-release dosage forms

Pharm. J.

(1982)

V. Bohner et al.

Paracellular transport and other mechanisms involved in intestinal peptide absorption

J. Brennan et al.

The comparative bioavailability of captopril after colonic infusion and oral administration in healthy volunteers

Clin. Pharmacol. Ther.

(1991)

D. Brockmeier et al.

Absorption of glibenclamide from different sites of the gastro-intestinal tract

Eur. J. Clin. Pharmacol.

(1985)

D. Brockmeier

In vitro/in vivo correlation of dissolution using moments of dissolution and transit times

Acta Pharm. Technol.

(1986)

D. Brockmeier et al.

Kinetics of piretanide absorption from the gastrointestinal tract

Meth. Find. Exp. Clin. Pharmacol.

(1986)

D. Brockmeier et al.

The absorption of piretanide from the gastro-intestinal tract is site-dependent

Eur. J. Clin. Pharmacol.

(1986)

H. Brondsted et al.

Hydrogels for site-specific drug delivery to the colon: in vitro and in vivo degradation

Pharm. Res.

(1992)

R. Cargill et al.

Controlled gastric emptying. I. Effects of physical properties on gastric residence times of nondisintegrating geometric shapes in beagle dogs

Pharm. Res.

(1988)

W.G. Chamblis

The forgotten dosage form: enteric-coated tablets

Pharm. Technol.

(1983)

K.K.C. Chan et al.

Site-differential gastrointestinal absorption of benazepril hydrochloride in healthy volunteers

Pharm. Res.

(1994)

W.L. Chiou

Effect of ‘unstirred’ water layer in the intestine on the rate and extent of absorption after oral absorption

Biopharm. Drug. Dispos.

(1994)

C.S. Cook et al.

Absorption and disposition of new antiarrhythmic agent bidisomide in man

Pharm. Res.

(1993)

C. Crevoisier et al.

Facteurs physico-chimiques susceptibles d'influencer l'absorption gastro-intestinale après dissolution des principes actifs

Pharm. Acta Helv.

(1976)

L. d'Agay-Abensour et al.

Absolute bioavailability of an aqueous solution of l-deamino-8-Darginine vasopressin from different regions of the gastrointestinal tract in man

Eur. J. Clin. Pharmacol.

(1993)

S.S. Davis et al.

Transit of pharmaceutical dosage forms through the small intestine

Gut

(1986)

Cited by (302)

Immunomodulatory effect and safety of TNF-α RNAi mediated by oral yeast microcapsules in rheumatoid arthritis therapy
2022, Materials Today Bio
Rheumatoid arthritis (RA) is a chronic autoimmune disease that requires long-term treatment and monitoring. Inhibition of inflammatory gene expression by gene therapy is a significant breakthrough in RA treatment, but the lack of a safe and effective gene delivery system hinders its application. Since oral administration can significantly reduce wound infection caused by parenteral administration, it also has the advantages of high patient compliance and convenience. Therefore, oral administration may be the best option for the treatment of this chronic disease. In this study, we developed a novel oral drug system by delivering tumor necrosis factor-α (TNF-α) short hairpin RNA (shRNA) mediated by non-pathogenic yeast to evaluate its regulation of systemic immune inflammation and safety in RA. Non-pathogenic yeast can resist the destruction of the gastrointestinal acid-base environment and can be recognized by the intestinal macrophages and act on systemic inflammatory lesions. Oral administration of yeast-mediated TNF-α shRNA significantly reduced the expression of TNF-α predominant pro-inflammatory factors in intestinal macrophages and joint synovium, and up-regulated the expression of anti-inflammatory cytokine IL-10 and M2 macrophages, systematically regulating the inflammatory response. This yeast-mediated oral gene delivery system can not only significantly inhibit knee joint synovial inflammation, but also has no toxic effects on peripheral blood and major organs. Therefore, yeast-mediated oral delivery of TNF-α shRNA may be used as a novel gene therapy strategy to treat RA through immunomodulating the mononuclear phagocyte system from the intestine to the joint synovium, and ultimately regulating systemic and local immune inflammation, providing new ideas for the clinical treatment of RA.
Administration strategies and smart devices for drug release in specific sites of the upper GI tract
2022, Journal of Controlled Release
Targeting the release of drugs in specific sites of the upper GI tract would meet local therapeutic goals, improve the bioavailability of specific drugs and help overcoming compliance-related limitations, especially in chronic illnesses of great social/economic impact and involving polytherapies (e.g. Parkinson's and Alzeimer's disease, tubercolosis, malaria, HIV, HCV). It has been traditionally pursued using gastroretentive (GR) systems, i.e. low-density, high-density, magnetic, adhesive and expandable devices. More recently, the interest towards oral administration of biologics has prompted the development of novel drug delivery systems (DDSs) provided with needles and able to inject different formulations in the mucosa of the upper GI tract and particularly of esophagus, stomach or small intestine. Besides comprehensive literature analysis, DDSs identified as smart devices in view of their high degree of complexity in terms of design, working mechanism, materials employed and manufacturing steps were discussed making use of graphic tools.
Stimuli-Responsive Microneedles as a Transdermal Drug Delivery System: A Demand-Supply Strategy
2022, Biomacromolecules
Microneedles are one of the most prominent approaches capable of physically disrupting the stratum corneum without devastating the deeper tissues to deliver both small molecules and macromolecules into the viable epidermis/dermis for local/systemic effects. Over the past two decades, microneedles have caught the attention of many researchers because of their outstanding advantages over oral and parenteral drug delivery systems such as self-administration, pain-free, steady-plasma concentration maintenance, avoidance of first-pass hepatic biotransformation, and so on. So far, scientists have reported various types of microneedle patches to deliver the loaded therapeutics as soon as the microneedles are inserted into the skin, regardless of the demand for therapeutics to treat a specific condition. This way of drug delivery can lead to potential risks such as poor therapeutic efficacy or drug overdose. The stimuli-responsive microneedles are the most predominant tool to achieve the on-demand/need-based drug delivery, leading to safe and effective treatment. Various natural and synthetic polymers that can undergo significant transitions such as swelling, shrinking, dissolution, or disintegration play a pivotal role in the development of stimuli-responsive microneedles. The current Review provides brief information about the history, emergence, type, and working principles of microneedles. Furthermore, it selectively discusses various exogenous and endogenous stimuli-responsive microneedles along with their mechanism of action involved in treating different disease conditions. Collaterally, the emergence of “closed-loop” combinatorial stimuli-responsive microneedle patches for precise delivery of therapeutics is meticulously canvassed. Subsequently, it covers the patents of different stimuli-responsive microneedles and further highlights the existing challenges and future perspectives concerning clinical application and large-scale production.
Expandable, dual-excipient fibrous dosage forms for prolonged delivery of sparingly-soluble drugs
2022, International Journal of Pharmaceutics
In this work, expandable fibrous dosage forms containing water-absorbing and fiber-strengthening excipients are investigated for prolonged delivery of sparingly-soluble drugs. The formulation comprised: sparingly-soluble ibuprofen drug; water-absorbing, high-molecular-weight hydroxypropyl methylcellulose (HPMC) excipient; and strengthening methacrylic acid-ethyl acrylate excipient. Upon immersion in a dissolution fluid, the single fibers and all the dosage forms (fiber volume fractions, φ = 0.16, 0.39, and 0.56) expanded roughly at the same rate. The size of the dosage forms doubled in fifteen minutes, and they were converted into a highly viscous gel. The gel was stabilized by the strengthening excipient for over two days. Eighty percent of the drug was released from single fibers in less than an hour, and in thirty-eight hours from the dosage form with φ = 0.56. Theoretical models suggest that if φ is small, drug release is limited by the diffusion of drug molecules through the thin fibers, which is fast. If φ is large, however, drug release is limited by the diffusion of drug molecules through the thick, monolithic dosage form gel, which is slow. Between these extremes, the drug release time increases exponentially with φ.
Mechanical strength and gastric residence time of expandable fibrous dosage forms
2022, International Journal of Pharmaceutics
Citation Excerpt :
Such dosage forms enable the release of drug into the stomach for prolonged time, and hence better control of drug absorption time and drug concentration in blood. This in turn enables improved efficacy, safety, and convenience of many prevailing drug therapies (Davis et al., 1986b; Davis et al., 1988; Rouge et al., 1996; Davis, 2005; Streubel et al., 2006). The concepts mostly examined for gastric retention are the mucoadhesive, floating, and expandable dosage forms.
Expandable, gastroretentive dosage forms are promising for precise control of drug concentration in blood. So far, however, short gastric residence times and safety considerations have limited their use. To mitigate such limitations, in this work expandable fibrous dosage forms were investigated for mechanical strength and gastric residence time in dogs. The fiber formulation comprised ibuprofen drug; water-absorbing, high-molecular-weight hydroxypropyl methylcellulose (HPMC) excipient; fiber-strengthening, enteric methacrylic acid-ethyl acrylate excipient; and barium sulfate, a gastrointestinal contrast agent. The fibers were coated either with a hydrophilic sugar, or with a strengthening enteric excipient. Upon administration to a dog, in the stomach the dosage form with sugar-coated fibers expanded to 1.7 times its initial radius in 50–100 minutes, and disintegrated after 4.8 hours. The dosage form with the enteric-excipient-coated fibers, by contrast, expanded to 1.6 times the initial radius in 5 hours, and fractured after 31 hours due to cyclic loads applied by the contracting stomach walls. The fragments passed into the small intestine where they dissolved in less than 2–3 hours. Diametral compression tests and dynamic fatigue failure models show that the substantial increase in gastric residence time is due to strengthening of the fibers by the enteric-excipient coating. Because the enteric excipient is a rubbery semi-solid in the acidic gastric fluid and dissolves in the pH-neutral intestinal fluids, safety concerns should be minimal. Thus, expandable fibrous dosage forms can be readily designed for prolonged, safe gastric retention.
The effect of weight reduction surgery on the efficacy and tolerability of epilepsy pharmacotherapy
2021, Epilepsy and Behavior
Bariatric surgery is an increasingly utilized procedure among patients with obesity-related medical complications. The impact of bariatric surgery on seizure frequency and antiseizure drug (ASD) levels are not well described.
We conducted a retrospective chart review of adult patients with a history of epilepsy or seizures undergoing bariatric surgery for morbid obesity from September 1997–September 2019. The median follow-up was 60 months [range 9–220 months].
Forty-six patients with a history of seizures were identified (38 female); 44 patients had recurrent and unprovoked seizures. Seventeen sets of pre- and post-surgery drug concentrations from 14 patients were reviewed. The median age at surgery was 44 years (range, 19–68). Thirty-three patients were prescribed ASDs at the time of bariatric surgery (median 1 drug [range, 1–3]). Laparoscopic Roux-en-Y was performed in 40 patients, and sleeve gastrectomy in 6 patients. Median pre-surgery weight was 120.75 kg (range, 71–230) and BMI 44.4 kg/m² (range, 34–77.6). Six months following surgery the median weight was 89.5 kg (range, 58.2–202) and BMI 34.2 kg/m² (range, 24.5–61.9).
Nine patients (19.6%) had a worsening of seizure control on long-term follow-up (median 60, range 9–220 months) following bariatric surgery, including five (10.8%) who suffered seizures within 6 months of bariatric surgery. Five patients developed ASD-associated side effects following bariatric surgery including irritability in two patients (levetiracetam and phenytoin) and one patient each suffering from somnolence (phenytoin), hyperammonemic encephalopathy (sodium valproate), and nausea and vomiting (carbamazepine). Subtherapeutic post-surgery drug concentrations were identified in 5 patients and supratherapeutic concentrations in one patient. In the initial 6 months following surgery, ASD doses were increased in five patients and reduced in five.
The majority of patients with epilepsy who undergo bariatric surgery have no change in seizure frequency. However, a significant minority of patients may experience medication side effects or an increase in seizure tendency due to the impact of bariatric surgery on ASD drug absorption and metabolism leading. Pre- and post-surgical serum concentrations should be measured in patients with seizures or epilepsy receiving ASDs.

View all citing articles on Scopus

View full text

Research paperDrug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery

Abstract

J. Pharm. Sci.

J. Pharm. Sci.

J. Pharm. Sci.

Int. J. Pharm.

J. Controlled Release

J. Pharm. Sci.

Gastroenterology

Int. J. Pharm.

Int. J. Pharm.

Int. J. Pharm.

J. Controlled Release

J. Pharm. Sci.

J. Pharm. Sci.

J. Pharm. Sci.

Mol. Immunol.

J. Pharm. Sci.

J. Pharm. Sci.

J. Controlled Release

Gastrointestinal Endoscopy

Int. J. Pharm.

J. Controlled Release

J. Controlled Release

Int. J. Pharm.

J. Controlled Release

J. Pharm. Sci.

Int. J. Pharm.

J. Pharm. Sci.

Int. J. Pharm.

Gastroenterology

Other methods in studying colonic drug absorption

Selective paracellular permeability in two models of intestinal absorption: cultured monolayers of human intestinal epithelial cells and rat intestinal segments

Pharm. Res.

Targeting drugs to the colon: delivery systems for oral administration

J. Drug Targeting

Pharmacokinetics of acrivastine after oral and colonic administration

J. Clin. Pharmacol.

Gut reaction to tablets and capsules. 2. Physiological factors and controlled-release dosage forms

Pharm. J.

Paracellular transport and other mechanisms involved in intestinal peptide absorption

The comparative bioavailability of captopril after colonic infusion and oral administration in healthy volunteers

Clin. Pharmacol. Ther.

Absorption of glibenclamide from different sites of the gastro-intestinal tract

Eur. J. Clin. Pharmacol.

In vitro/in vivo correlation of dissolution using moments of dissolution and transit times

Acta Pharm. Technol.

Kinetics of piretanide absorption from the gastrointestinal tract

Meth. Find. Exp. Clin. Pharmacol.

The absorption of piretanide from the gastro-intestinal tract is site-dependent

Eur. J. Clin. Pharmacol.

Hydrogels for site-specific drug delivery to the colon: in vitro and in vivo degradation

Pharm. Res.

Controlled gastric emptying. I. Effects of physical properties on gastric residence times of nondisintegrating geometric shapes in beagle dogs

Pharm. Res.

The forgotten dosage form: enteric-coated tablets

Pharm. Technol.

Site-differential gastrointestinal absorption of benazepril hydrochloride in healthy volunteers

Pharm. Res.

Effect of ‘unstirred’ water layer in the intestine on the rate and extent of absorption after oral absorption

Biopharm. Drug. Dispos.

Absorption and disposition of new antiarrhythmic agent bidisomide in man

Pharm. Res.

Facteurs physico-chimiques susceptibles d'influencer l'absorption gastro-intestinale après dissolution des principes actifs

Pharm. Acta Helv.

Absolute bioavailability of an aqueous solution of l-deamino-8-Darginine vasopressin from different regions of the gastrointestinal tract in man

Eur. J. Clin. Pharmacol.

Transit of pharmaceutical dosage forms through the small intestine

Gut

Research paper
Drug absorption sites in the gastrointestinal tract and dosage forms for site-specific delivery